Targeting IL-23 Succeeds in Psoriatic Arthritis

(MedPage Today) -- The monoclonal antibody risankizumab (Skyrizi) showed significant efficacy for psoriatic arthritis (PsA) in two phase III randomized trials, a researcher reported.
In the KEEPSAKE 1 and 2 trials, 1,407 patients with active PsA...